Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model
1996

Effect of Batimastat on Colorectal Cancer

Sample size: 60 publication Evidence: moderate

Author Information

Author(s): SA Watson, TM Morris, SL Parsons, RJC Steele, PD Brown

Primary Institution: Cancer Studies Unit, Department of Surgery, Queen's Medical Centre, Nottingham

Hypothesis

Can the matrix metalloproteinase inhibitor batimastat reduce ascites and solid tumor growth in a colorectal cancer model?

Conclusion

Batimastat significantly reduced ascites volume and solid tumor deposits in a colorectal cancer model when administered from the start of treatment.

Supporting Evidence

  • Batimastat reduced ascites volume to 21% of control when administered from day 0.
  • Solid tumor deposits were reduced to 77% of control with batimastat from day 0.
  • Treatment from day 10 did not significantly affect ascites volume.

Takeaway

Batimastat is a medicine that helps shrink tumors and reduce fluid buildup in the belly for mice with colon cancer.

Methodology

The study used SCID mice injected with a human colorectal cancer cell line and treated with batimastat to assess its effects on ascites and tumor growth.

Limitations

The study was conducted in mice, which may not fully represent human responses.

Participant Demographics

60 female SCID mice, aged 6-10 weeks.

Statistical Information

P-Value

<0.002

Statistical Significance

p<0.002

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication